[1] |
WENG Junyong, YE Zilan, ZHANG Ruoxin, LIU Qi, LI Xinxiang.
Exploring the guiding role of the number of adverse pathological features in risk stratification for recurrence of stage Ⅰ-Ⅲ colorectal cancer: a retrospective cohort study of 9 875 cases
[J]. China Oncology, 2024, 34(6): 527-536.
|
[2] |
TANG Duocai, ZHOU Shukui, ZHANG Guiyin, LIU Lei, LIAO Hong.
Analysis of risk factors of recurrence in non-muscle invasive bladder cancer patients after initial transurethral resection of bladder tumor
[J]. China Oncology, 2023, 33(5): 478-483.
|
[3] |
DONG Xiaohuan, LIU Jun, LI Hongxuan, CHENG Yan, LI Yue, YU Wen, CAI Xuwei, FU Xiaolong.
Preliminary study on involving field irradiation radiotherapy in neoadjuvant chemoradiotherapy for esophageal cancer
[J]. China Oncology, 2023, 33(3): 267-273.
|
[4] |
CAO Mengxuan, HU Can, ZHANG Yanqiang, HUANG Ling, DU Yian, YU Pengcheng, ZHANG Ruolan, XU Zhiyuan, CHENG Xiangdong.
Analysis of risk factors of early recurrence and metastasis after radical resection of gastric cancer
[J]. China Oncology, 2022, 32(7): 588-595.
|
[5] |
LI Ting, XU Yu, JIA Dongdong, LIAO Zhichao, SUN Wei, WU Haixiao, REN Zhiwu, ZHAO Jun, XING Ruwei, TENG Sheng, YANG Yun, CHEN Yong, LI Tao, YANG Jilong.
Adjuvant therapy with anti-PD-1 antibody vs targeted therapy for patients with resected stage Ⅲ malignant melanoma: a real-world data analysis from China centers
[J]. China Oncology, 2022, 32(12): 1147-1157.
|
[6] |
ZHAO Mingming, WANG Tianyou, WANG Chao.
Progress in menopausal hormone therapy for postoperative patients with gynecological malignant cancer
[J]. China Oncology, 2022, 32(11): 1098-1104.
|
[7] |
LIN Yi, WANG Ce, KANG Xun, KANG Zhuang, CHEN Feng, JIANG Bo, LI Wenbin.
Screening recurrent glioblastoma-related genes and analyzing their gene expressions in association with clinicopathological parameters and prognosis
[J]. China Oncology, 2022, 32(1): 13-23.
|
[8] |
LI Zeng , WU Yi , CHEN Zhuzhong , CHEN Li , LIAO Hong , MAO Dun , XIAO Yingming , XIE Hongping , LI Xiuli , YANG Shengke , ZHOU Shukui , ZHONG Lei , LU Hao , CHEN Yongji .
The value of 18 F-PSMA-1007 PET/CT in the early diagnosis and clinical treatment of patients with biochemical recurrence after radical prostatectomy
[J]. China Oncology, 2021, 31(11): 1081-1087.
|
[9] |
LU Xiaoteng, XU Qing.
A study on factors associated with recurrence of non-small cell lung cancer based on CT image features
[J]. China Oncology, 2020, 30(8): 636-640.
|
[10] |
CHEN Yang , LIU Wei , LI Ruimin , WANG Qifeng , SHEN Xigang , TANG Wei .
Radiogenomics: association between BI-RADS mammographic imaging features and the 21-gene recurrence score
[J]. China Oncology, 2020, 30(7): 505-511.
|
[11] |
QIU Xiaoyang , WANG Shaohong , ZHENG Jing , WU Xuan , WANG Yuanyuan , LIU Jun , YE Caiguo .
Predictive value of immunocytochemical p16/Ki-67 double staining for cervical cytology negative and HR-HPV positive shunting and histological LSIL prognosis
[J]. China Oncology, 2020, 30(7): 512-518.
|
[12] |
FENG Zheng, WU Xiaohua.
Hematological toxicities of maintenance PARP inhibitors for patients with platinum-sensitive recurrent ovarian cancer
[J]. China Oncology, 2020, 30(4): 299-304.
|
[13] |
LIU Shan, FANG Juan, WANG Lili, ZHANG Yinghong, DU Wenjie, ZHU Taohua.
Association between peripheral nerve invasion and recurrence risk factors in cervical cancer
[J]. China Oncology, 2019, 29(6): 439-444.
|
[14] |
XU Ye, ZHOU Yang, TANG Na, et al.
Value of preoperative magnetic resonance imaging in predicting postoperative recurrence and metastasis of middle rectal cancer
[J]. China Oncology, 2018, 28(5): 376-382.
|
[15] |
LIN Xuedan, YANG Tianxing,TAO Zhihua.
Predictive value of CEA and CA19-9 for recurrence in stage Ⅱ-Ⅲ colon cancer
[J]. China Oncology, 2018, 28(11): 827-832.
|